Interleukin-33 inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Interleukin-33 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Interleukin-33 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Interleukin-33 inhibitors: Overview
IL-33 belongs to the IL-1 family of cytokines. IL-33 is a novel cytokine that signals through the ST2 surface receptor. IL-33 receptor has a single chain, which is also related to the IL-1 receptor (interleukin-1 receptor-like 1, IL-1RL1). Signal transduction upon ligand binding involves the Toll-like receptor (TIR) domain of the receptor chain and resembles that of IL-1 and IL-18, and TLRs. IL-33 exhibits diverse immune regulatory functions during the various phases of different diseases. IL-33 likely functions as a disease sensitizer and plays pathological roles in inflamed tissues in allergic disorders that involve hyperreactive immune responses. In contrast, IL-33 also mediates tissue-protective functions during the recovery phase following tissue injury, which involves activation of tissue-reparative M2 macrophages, ILC2s, and Tregs. IL-33 could be used against inflammation caused by Th1 response, and antagonists perhaps might be developed as anti-allergic compounds. Targeting the IL-33-ST2 axis using monoclonal antibodies (or small-molecule inhibitors) could prove to be an effective strategy against COVID-19 virus. The combination of IL-33 blockade with other therapeutics could be an option for the efficacious treatment of inflammatory diseases.
Report Highlights
This segment of the Interleukin-33 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin-33 inhibitors Emerging Drugs
Further product details are provided in the report……..
Interleukin-33 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin-33 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Interleukin-33 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin-33 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-33 inhibitors drugs.
Interleukin-33 inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Interleukin-33 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Interleukin-33 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Interleukin-33 inhibitors: Overview
IL-33 belongs to the IL-1 family of cytokines. IL-33 is a novel cytokine that signals through the ST2 surface receptor. IL-33 receptor has a single chain, which is also related to the IL-1 receptor (interleukin-1 receptor-like 1, IL-1RL1). Signal transduction upon ligand binding involves the Toll-like receptor (TIR) domain of the receptor chain and resembles that of IL-1 and IL-18, and TLRs. IL-33 exhibits diverse immune regulatory functions during the various phases of different diseases. IL-33 likely functions as a disease sensitizer and plays pathological roles in inflamed tissues in allergic disorders that involve hyperreactive immune responses. In contrast, IL-33 also mediates tissue-protective functions during the recovery phase following tissue injury, which involves activation of tissue-reparative M2 macrophages, ILC2s, and Tregs. IL-33 could be used against inflammation caused by Th1 response, and antagonists perhaps might be developed as anti-allergic compounds. Targeting the IL-33-ST2 axis using monoclonal antibodies (or small-molecule inhibitors) could prove to be an effective strategy against COVID-19 virus. The combination of IL-33 blockade with other therapeutics could be an option for the efficacious treatment of inflammatory diseases.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin-33 inhibitors R&D. The therapies under development are focused on novel approaches for Interleukin-33 inhibitors.
This segment of the Interleukin-33 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin-33 inhibitors Emerging Drugs
- MEDI3506: AstraZeneca
- Itepekimab: Regeneron Pharmaceuticals/Sanofi
Further product details are provided in the report……..
Interleukin-33 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin-33 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Interleukin-33 inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Interleukin-33 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin-33 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-33 inhibitors drugs.
Interleukin-33 inhibitors Report Insights
- Interleukin-33 inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Interleukin-33 inhibitors drugs?
- How many Interleukin-33 inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Interleukin-33 inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin-33 inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Interleukin-33 inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- AstraZeneca
- Regeneron Pharmaceuticals
- Sanofi
- Genentech
- Cantargia
- MEDI3506
- Itepekimab
- Astegolimab
- CAN-10
- Research program: IL1RAP-targeting antibody therapeutics
Introduction
Executive Summary
Interleukin-33 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Interleukin-33 inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Interleukin-33 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Interleukin-33 inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Itepekimab: Regeneron Pharmaceuticals/Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MEDI3506: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CAN-10: Cantargia
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interleukin-33 inhibitors Key Companies
Interleukin-33 inhibitors Key Products
Interleukin-33 inhibitors- Unmet Needs
Interleukin-33 inhibitors- Market Drivers and Barriers
Interleukin-33 inhibitors- Future Perspectives and Conclusion
Interleukin-33 inhibitors Analyst Views
Interleukin-33 inhibitors Key Companies
Appendix
Executive Summary
Interleukin-33 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Interleukin-33 inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Interleukin-33 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Interleukin-33 inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Itepekimab: Regeneron Pharmaceuticals/Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MEDI3506: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CAN-10: Cantargia
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interleukin-33 inhibitors Key Companies
Interleukin-33 inhibitors Key Products
Interleukin-33 inhibitors- Unmet Needs
Interleukin-33 inhibitors- Market Drivers and Barriers
Interleukin-33 inhibitors- Future Perspectives and Conclusion
Interleukin-33 inhibitors Analyst Views
Interleukin-33 inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Interleukin-33 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Interleukin-33 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Interleukin-33 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Interleukin-33 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products